icon-    folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections (CROI)
Boston, Massachusetts
March 4-7, 2018
Back grey_arrow_rt.gif
 
 
 
IBALIZUMAB SUSCEPTIBILITY IN PATIENT HIV ISOLATES RESISTANT TO ANTIRETROVIRALS
 
 
 
 
Reported by Jules Levin
CROI 2018 March 4-7 Boston MA
 
S. WEINHEIMER1, C. MARSOLAIS2, Z. COHEN2, S. LEWIS1
1TaiMed Biologics, Irvine, CA, 2Theratechnologies, Montreal, Canada.
 
"Patients receiving their current failing ARV therapy, or no therapy, were monitored during a 7-day control period. Thereafter, a loading dose of 2,000 mg of intravenous (IV) IBA was the only ARV agent added to their regimen for 7 days. IBA was continued at doses of 800 mg IV every 2 weeks through 24 weeks on study treatment."

AASDL1

AASDL2

AASDL3

AASDL4

AASDL5

AASDL6